BiotechTube
Home/Kallyope/Patrick Flanigan
PF

Patrick Flanigan

Chief Financial Officer

Kallyope

Therapeutic Areas

MigraineMetabolic Disorders

Kallyope Pipeline

DrugIndicationPhase
Elismetrep (K-304)Acute Treatment of MigrainePhase 2
K-554Metabolic Disorders / ObesityPreclinical
Undisclosed Metabolic ProgramMetabolic DisordersDiscovery

Leadership Team at Kallyope

JG
Jay Galeota
CEO & President
BL
Brett Lauring, M.D., Ph.D.
Chief Medical Officer
SP
Shirly Pinto, Ph.D.
Chief Scientific Officer
FH
Franz Humer, Ph.D.
Chair, Board of Directors
View full Kallyope profile